Eps8L3 Inhibitors

Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) pathway. By inhibiting EGFR, erlotinib leads to a downregulation of several downstream signaling pathways including the Ras/Raf/MEK/ERK pathway, which can decrease the functional activity of Eps8L3 involved in actin cytoskeletal remodeling.

Sorafenib is a multi-kinase inhibitor that targets Raf kinases within the Ras/Raf/MEK/ERK signaling cascade. Its action diminishes the signaling through this pathway, thereby indirectly inhibiting the activity of Eps8L3 by reducing the availability of signaling molecules necessary for its functional role in actin filament capping and bundling.

Gefitinib selectively inhibits EGFR tyrosine kinase, which in turn reduces the activation of downstream pathways, including the PI3K/Akt pathway. This results in a decrease in Eps8L3 function, as this protein is implicated in the regulation of actin dynamics that are influenced by the PI3K/Akt pathway.

Lapatinib is a dual inhibitor of EGFR and HER2 tyrosine kinases. By diminishing the activity of these receptors, lapatinib indirectly suppresses downstream signaling pathways, including the Ras/Raf/MEK/ERK pathway, which subsequently leads to decreased functional activity of Eps8L3 that is involved in the modulation of growth factor receptor signaling transduction.

Imatinib is a selective inhibitor of certain tyrosine kinases including BCR-ABL, c-Kit, and PDGFR. By inhibiting these kinases, imatinib can affect the actin cytoskeleton remodeling processes in which Eps8L3 is implicated, leading to an indirect decrease in Eps8L3's functional activity.

Dasatinib is a multi-targeted inhibitor of several Src family kinases and BCR-ABL. It reduces the phosphorylation of downstream targets involved in actin filament formation and stabilization, thereby indirectly inhibiting the activity of Eps8L3, which is associated with the regulation of actin cytoskeletal dynamics.

Nilotinib is a selective inhibitor of BCR-ABL tyrosine kinase. By suppressing this kinase, nilotinib indirectly diminishes the Ras/Raf/MEK/ERK signaling cascade, which can lead to decreased functional activity of Eps8L3, a protein involved in the modulation of actin dynamics.

AP 24534 is a multi-targeted tyrosine kinase inhibitor that affects BCR-ABL and other kinases. Its inhibition of these kinases indirectly leads to reduced actin cytoskeletal dynamics, thereby diminishing the functional activity of Eps8L3, which is implicated in growth factor receptor signaling transduction and actin remodeling.

PD 0332991 is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Its inhibition of cell cycle progression can indirectly affect the functional activity of Eps8L3 by altering the dynamics of actin cytoskeleton remodeling, which Eps8L3 is known to modulate.

Cobimetinib is a MEK inhibitor that diminishes the MAPK/ERK signaling pathway. As Eps8L3 functions within the downstream effects of this pathway, particularly in actin filament dynamics, cobimetinib indirectly leads to a decrease in the functional activity of Eps8L3.